ArticleFrontiers in endocrinology2026
TyHGB and CVD high-risk stratification: nonlinear association and discrimination in the ChinaHEART Luohe study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: TyHGB is a composite metabolic index integrating triglyceride-to-high-density lipoprotein cholesterol ratio, fasting plasma glucose, and body mass index, but its association with World Health Organization (WHO)-defined cardiovascular disease (CVD) high-risk status in community settings remains unclear. Methods: We analyzed 6,755 adults from a community-based ChinaHEART Luohe screening cohort (2021-2022). CVD high-risk was defined as an estimated 10-year WHO CVD risk ≥20%. TyHGB was examined per 1-unit increase and as high versus low using a receiver operating characteristic (ROC)-derived cutoff (Youden index; approximately 7.6). Logistic regression and restricted cubic splines were used to assess associations and potential nonlinearity. Discrimination was evaluated using ROC curves with DeLong's tests, and incremental value beyond conventional risk factors was assessed using integrated discrimination improvement (IDI) and net reclassification improvement (NRI). Results: The prevalence of CVD high-risk was 22%. TyHGB was independently associated with CVD high-risk (fully adjusted OR 1.131 per 1-unit increase), and high TyHGB (≥7.6) was associated with higher odds (OR 1.642). In unadjusted analyses, TyHGB showed higher discrimination than TyG (AUC 0.624 vs 0.585). Adding TyHGB to the base model modestly improved reclassification (IDI 0.003; NRI 0.216). TyHGB was also retained in exploratory machine-learning analyses. Discussion: TyHGB was positively associated with WHO-defined CVD high-risk and provided modest incremental discrimination and reclassification for cross-sectional high-risk classification beyond conventional risk factors, supported by sensitivity analyses. These findings relate to estimated risk status rather than adjudicated incident CVD events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.